Evidence map›Paper›PMID 42769841›Full record

ReviewFrontiers in oncology2026

Advances in locoregional surgical treatment of

Shushu Liu, Mancheng Yu, Zirui Ke, Jingru Wang, Wei Zhong, Wei Wang

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shushu LiuBreast cancer center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, Wuhan, China.
Mancheng YuBreast cancer center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, Wuhan, China.
Zirui KeBreast cancer center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, Wuhan, China.
Jingru WangBreast cancer center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, Wuhan, China.
Wei ZhongBreast cancer center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, Wuhan, China.
Wei WangBreast cancer center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Breast cancer is the most common malignancy among women worldwide. A notable subset of patients presents with Methodology: Recent retrospective and prospective studies on locoregional surgery for Results: Most retrospective studies and meta-analyses report that primary breast surgery is associated with improved prognosis when stage IV disease is first diagnosed. However, significant selection bias exists in these data. Women who undergo surgery tend to be younger, have smaller primary tumors, fewer comorbidities, and lower metastatic burden-particularly fewer visceral metastases. They are also more likely to receive higher-quality overall care. These factors suggest that surgeons preferentially select patients with a better expected prognosis for surgery. In contrast, prospective randomized trials have consistently failed to demonstrate that locoregional surgery provides additional survival benefits beyond systemic therapy alone. Consequently, routine locoregional surgical treatment is not recommended for most patients with Conclusion: Although retrospective analyses support a survival advantage from locoregional surgery in

Indexed as

bone-only metastasesde-novo stage IV breast cancerlocoregional surgeryprimary tumor resectionprospective study

Identifiers

PMID42769841
PMCPMC13591408

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.